Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Phase 1 Recruiting
24 enrolled
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Phase 1/2 Recruiting
15 enrolled
DP-04
Recruiting
100 enrolled
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Phase 2 Recruiting
25 enrolled
3D Printed Custom Applicators for HDR BT (DISCO)
Phase NA Recruiting
10 enrolled
iCaRe2
Recruiting
999,999 enrolled
Image-Guided Gynecologic Brachytherapy
Phase NA Recruiting
54 enrolled
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Phase 2 Recruiting
32 enrolled
EMBRAVE
Recruiting
300 enrolled
TRIDENT
Recruiting
278 enrolled
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Phase 1 Recruiting
30 enrolled
MIPEX
Phase NA Recruiting
64 enrolled
ASQ-GYO
Phase NA Recruiting
70 enrolled
DOVE
Phase 2 Recruiting
198 enrolled
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
Phase NA Recruiting
192 enrolled
NYSCF Scientific Discovery Biobank
Recruiting
10,000 enrolled
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Recruiting
6,000 enrolled
A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer
Phase 2 Recruiting
40 enrolled
HPV-VIM
Phase 2 Recruiting
85 enrolled
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
Phase 1 Recruiting
18 enrolled
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Phase 3 Recruiting
8,000 enrolled
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Phase 3 Recruiting
1,200 enrolled
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Phase 3 Recruiting
1,348 enrolled
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
Recruiting
600 enrolled
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
Phase 1 Recruiting
32 enrolled
RetroBT
Recruiting
300 enrolled